Anika Therapeutics (ANIK)
Anika Therapeutics Revenues: 14.36M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ANIK Revenues Rankings
| Overall | 17th percentile | 3650 of 4425 |
| Sector | 38th percentile | 288 of 470 in Healthcare |
| Industry | 59th percentile | 54 of 132 in Biotechnology |
ANIK Revenues Range, Past 5 Years
| Minimum | 7.100M | Jun 2007 |
| Maximum | 18.46M | Sep 2011 |
| Average | 11.77M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ANIK related companies
ANIK News
Morning Movers 05/14: (GOLF) (VTUS) (KERX) Higher; (IOC) (ACOM) (ANIK) Lower
May 14, 10:07AM Street Insider
May 14, 10:07AM Street Insider
$anik has had a nice run up today to $15.42 but has retreated to $15.06. Resistance at $15.17.
about 17 days ago by maxwellhsu
about 17 days ago by maxwellhsu
Anika Therapeutics' CEO Discusses Q1 2012 Results - Earnings Call Transcript
May 04, 12:38PM Seeking Alpha
May 04, 12:38PM Seeking Alpha
Morning Movers 05/04: (LF) (POWI) (MITK) (SPRD) Higher; (BODY) (INVN) (BONE) (CHEF) Lower
May 04, 11:31AM Street Insider
May 04, 11:31AM Street Insider
Anika Therapeutics Announces Date of First-Quarter 2012 Financial Results Conference Call
Apr 26, 8:00AM Business Wire
Apr 26, 8:00AM Business Wire
A new monster begins to emerge. $ANIK is number 61 today and breaking out big time. No postion
about 46 days ago by billgunderson
about 46 days ago by billgunderson
Anika Therapeutics' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mar 01, 6:40PM Seeking Alpha
Mar 01, 6:40PM Seeking Alpha
$ANIK...Anika Therapeutics reports 25 % increase in sales Q4...21c vs est of 11c. gross margins improved 700 basis pts to 59.8% from 52.8%
about 87 days ago by stocktilludrop
about 87 days ago by stocktilludrop
Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2011 Financial Results Conference Call
Feb 23, 9:08AM Business Wire
Feb 23, 9:08AM Business Wire
$ANIK with a 72c street est growing YOY @ 24 % in tissue repair based on HA no reason why it can't trade 25 pe
about 110 days ago by stocktilludrop
about 110 days ago by stocktilludrop
Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on February 7
Feb 02, 1:00PM Business Wire
Feb 02, 1:00PM Business Wire
$ANIK ...continue strength off its 20 day MA ...could be explosive drive through $10
about 115 days ago by stocktilludrop
about 115 days ago by stocktilludrop
$ANIK above its 20 day ma @ 8.40 ..setting up for explosive move through $ 10 at some point soon.
about 116 days ago by stocktilludrop
about 116 days ago by stocktilludrop
Anika Therapeutics to Present at the Eighth Annual Noble Financial Equity Conference on January 17
Jan 10, 10:48AM Business Wire
Jan 10, 10:48AM Business Wire
Anika (ANIK) Signs Distribution Agreement with DePuy Mitek for MONOVISC
Dec 21, 3:35PM Street Insider
Dec 21, 3:35PM Street Insider
Anika Therapeutics Announces U.S. MONOVISC License and Supply Agreement with DePuy Mitek
Dec 21, 3:34PM Benzinga
Dec 21, 3:34PM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANIK | 13.63 | +0.02 | +0.15% | 186.32M |
| ANH | 6.73 | +0.02 | +0.30% | 909.56M |
| ANGO | 12.20 | -0.13 | -1.05% | 306.46M |
| ANGN | 5.85 | +0.20 | +3.54% | 22.93M |
| ANF | 36.23 | +0.94 | +2.66% | 3.069B |
| ANEN | 19.05 | +0.06 | +0.32% | 283.65M |
| ASPS | 57.98 | -1.04 | -1.76% | 1.352B |
| ASP | 11.61 | -0.05 | -0.46% | |
| ASNA | 18.90 | -0.02 | -0.11% | 2.896B |
| ASML | 46.00 | -0.22 | -0.48% | 19.03B |
